US Patent

US12280056 — Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Method of Use · Assigned to Amgen Inc · Expires 2039-11-18 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a combination therapy that includes a KRASG12C inhibitor, such as Lumakras, and one or more additional active agents for treating cancers.

USPTO Abstract

The present invention provides combination therapy that includes an KRASG12C inhibitor, such asor a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4107 — Lumakras
U-4107 — Lumakras
U-4107 — Lumakras

Patent Metadata

Patent number
US12280056
Jurisdiction
US
Classification
Method of Use
Expires
2039-11-18
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.